Evidence map›Paper›PMID 33077647›Full record

ArticleAntimicrobial agents and chemotherapy2020

Regioisomerization of Antimalarial Drug WR99210 Explains the Inactivity of a Commercial Stock.

T Parks Remcho, Sravanthi D Guggilapu, Phillip Cruz, Glenn A Nardone, Gavin Heffernan, Robert D O'Connor, Carole A Bewley, Thomas E Wellems, Kristin D Lane

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Antiplasmodial Compounds fromInternational journal of molecular sciences · 2026
    Article
  2. To quest new targets ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024
    Review
  3. CRISPR/Cas9 Editing of the Plasmodium falciparum Genome.Methods in molecular biology (Clifton, N.J.) · 2022
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

T Parks Remcho *Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0002-9576-2205
Sravanthi D Guggilapu *Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-1910-4822
Phillip CruzOffice of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Glenn A NardoneResearch Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Gavin HeffernanJacobus Pharmaceutical Company, Inc., Princeton, New Jersey, USA.
Robert D O'ConnorLaboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Carole A BewleyLaboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-2203-0852
Thomas E WellemsLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA twellems@niaid.nih.gov kristin.lane@nih.gov.ORCID 0000-0003-3899-8454
Kristin D LaneLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA twellems@niaid.nih.gov kristin.lane@nih.gov.ORCID 0000-0002-4352-0562
National Institutes of Health · USJacobi Medical Center · US

Funding

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
NIGMS NIH HHS R01 GM129325
6 · The paper itself

Abstract

WR99210, a former antimalarial drug candidate now widely used for the selection of

Indexed as

AntimalarialsFolic Acid AntagonistsMalaria, FalciparumDrug ResistanceHumansPlasmodium falciparumTetrahydrofolate DehydrogenaseThymidylate SynthaseTriazinesAntimalarialsFolic Acid AntagonistsTetrahydrofolate DehydrogenaseThymidylate SynthaseTriazinesantimalarial agentsdihydrofolate reductasenuclear magnetic resonancePlasmodium falciparumtransformation methodstriazines

Identifiers

PMID33077647
PMCPMC7927815
OpenAlexW3093359390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.